Discontinued — last reported Q4 '22
Eli Lilly Other Working Capital decreased by 100.0% to $0.00 in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $542.80M to $0.00. Over 4 years (FY 2021 to FY 2025), Other Working Capital shows an upward trend with a 7.4% CAGR.
Positive changes suggest a source of cash from optimizing minor balance sheet items, while negative changes indicate cash is being tied up in these categories.
The aggregate net change in miscellaneous operating assets and liabilities not specifically categorized in major line it...
This is often used to reconcile net income to cash flow and varies based on a company's specific accounting classifications for 'other' items.
cf_change_in_other_working_capital| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $188.50M | $185.10M | $6.70M | $32.60M | -$81.80M | $266.80M | $87.20M | $168.30M | -$550.70M | $485.60M | $192.30M | $298.60M | -$31.90M | -$32.10M | $542.80M | $324.80M | $54.40M | $302.30M | $0.00 |
| QoQ Change | — | -1.8% | -96.4% | +386.6% | -350.9% | +426.2% | -67.3% | +93.0% | -427.2% | +188.2% | -60.4% | +55.3% | -110.7% | -0.6% | >999% | -40.2% | -83.3% | +455.7% | -100.0% |
| YoY Change | — | — | — | — | -143.4% | +44.1% | >999% | +416.3% | -573.2% | +82.0% | +120.5% | +77.4% | +94.2% | -106.6% | +182.3% | +8.8% | +270.5% | >999% | -100.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.